UK firms welcome new price increase deal:
This article was originally published in Clinica
Executive Summary
Companies in the UK have welcomed the introduction of a new mechanism for establishing annual price increases for healthcare products prescribed by GPs and reimbursed by the government. Under an agreement with the Department of Health's Drug Tariff Section, companies will use a formula for establishing the maximum available price increase for products such as glucose testing strips and hypodermic syringes and needles. The formula consists of the "GDP deflator", which is currently 2.75%, minus an agreed "efficiency deduction" of 0.75%. The Association of British Health-Care Industries comments that this is the first time it has had a dedicated group lobby for a price increase. The agreement, which will be reviewed after three years, covers products listed under part IX of the Drug Tariff.
You may also be interested in...
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.